CEUS cardiac exam protocols International Contrast Ultrasound Society (ICUS) recommendations.

IF 3.2 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Echo Research and Practice Pub Date : 2022-08-23 DOI:10.1186/s44156-022-00008-3

Thomas R Porter, Steven B Feinstein, Roxy Senior, Sharon L Mulvagh, Petros Nihoyannopoulos, Jordan B Strom, Wilson Mathias, Beverly Gorman, Arnaldo Rabischoffsky, Michael L Main, Andrew Appis

{"title":"CEUS cardiac exam protocols International Contrast Ultrasound Society (ICUS) recommendations.","authors":"Thomas R Porter, Steven B Feinstein, Roxy Senior, Sharon L Mulvagh, Petros Nihoyannopoulos, Jordan B Strom, Wilson Mathias, Beverly Gorman, Arnaldo Rabischoffsky, Michael L Main, Andrew Appis","doi":"10.1186/s44156-022-00008-3","DOIUrl":null,"url":null,"abstract":"<p><p>The present CEUS Cardiac Exam Protocols represent the first effort to promulgate a standard set of protocols for optimal administration of ultrasound enhancing agents (UEAs) in echocardiography, based on more than two decades of experience in the use of UEAs for cardiac imaging. The protocols reflect current clinical CEUS practice in many modern echocardiography laboratories throughout the world. Specific attention is given to preparation and dosing of three UEAs that have been approved by the United States Food and Drug Administration (FDA) and additional regulatory bodies in Europe, the Americas and Asia-Pacific. Consistent with professional society guidelines (J Am Soc Echocardiogr 31:241-274, 2018; J Am Soc Echocardiogr 27:797-810, 2014; Eur Heart J Cardiovasc Imaging 18:1205, 2017), these protocols cover unapproved \"off-label\" uses of UEAs-including stress echocardiography and myocardial perfusion imaging-in addition to approved uses. Accordingly, these protocols may differ from information provided in product labels, which are generally based on studies performed prior to product approval and may not always reflect state of the art clinical practice or guidelines.</p>","PeriodicalId":45749,"journal":{"name":"Echo Research and Practice","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2022-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396906/pdf/","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Echo Research and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s44156-022-00008-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 3

Abstract

The present CEUS Cardiac Exam Protocols represent the first effort to promulgate a standard set of protocols for optimal administration of ultrasound enhancing agents (UEAs) in echocardiography, based on more than two decades of experience in the use of UEAs for cardiac imaging. The protocols reflect current clinical CEUS practice in many modern echocardiography laboratories throughout the world. Specific attention is given to preparation and dosing of three UEAs that have been approved by the United States Food and Drug Administration (FDA) and additional regulatory bodies in Europe, the Americas and Asia-Pacific. Consistent with professional society guidelines (J Am Soc Echocardiogr 31:241-274, 2018; J Am Soc Echocardiogr 27:797-810, 2014; Eur Heart J Cardiovasc Imaging 18:1205, 2017), these protocols cover unapproved "off-label" uses of UEAs-including stress echocardiography and myocardial perfusion imaging-in addition to approved uses. Accordingly, these protocols may differ from information provided in product labels, which are generally based on studies performed prior to product approval and may not always reflect state of the art clinical practice or guidelines.

查看原文本刊更多论文

国际对比超声学会(ICUS)推荐的超声造影心脏检查方案。

目前的超声造影心脏检查方案是基于超声心动图超声增强剂(uea)在心脏成像中使用20多年的经验，首次努力颁布一套超声心动图超声增强剂(uea)的最佳管理标准方案。该方案反映了目前世界上许多现代超声心动图实验室的临床超声造影实践。特别关注美国食品和药物管理局(FDA)以及欧洲、美洲和亚太其他管理机构批准的三种uea的制备和剂量。《中华医学会心脏科杂志》，2018;中华医学会心脏科杂志，2014;Eur Heart J cardiovascular Imaging 18:20 5, 2017)，这些方案涵盖了除批准用途外，未批准的“标签外”使用uas，包括应激超声心动图和心肌灌注成像。因此，这些方案可能与产品标签上提供的信息不同，产品标签通常基于产品批准前进行的研究，可能并不总是反映最先进的临床实践或指南。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Echo Research and Practice CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

6.70

自引率

12.70%

发文量

审稿时长

8 weeks

期刊介绍： Echo Research and Practice aims to be the premier international journal for physicians, sonographers, nurses and other allied health professionals practising echocardiography and other cardiac imaging modalities. This open-access journal publishes quality clinical and basic research, reviews, videos, education materials and selected high-interest case reports and videos across all echocardiography modalities and disciplines, including paediatrics, anaesthetics, general practice, acute medicine and intensive care. Multi-modality studies primarily featuring the use of cardiac ultrasound in clinical practice, in association with Cardiac Computed Tomography, Cardiovascular Magnetic Resonance or Nuclear Cardiology are of interest. Topics include, but are not limited to: 2D echocardiography 3D echocardiography Comparative imaging techniques – CCT, CMR and Nuclear Cardiology Congenital heart disease, including foetal echocardiography Contrast echocardiography Critical care echocardiography Deformation imaging Doppler echocardiography Interventional echocardiography Intracardiac echocardiography Intraoperative echocardiography Prosthetic valves Stress echocardiography Technical innovations Transoesophageal echocardiography Valve disease.